Alzheimer's Biomarker Testing Risks for Healthy Adults
Before seeking testing for Alzheimer's, adults should consider the limitations and potential insurance coverage gaps.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Would you want to know if you are at risk for a disease before symptoms appear?
A JAMA Viewpoint published on Oct. 19, 2026, highlights the ethical risks of using Alzheimer's biomarker testing in people who show no cognitive symptoms. While these tests can detect brain changes, they are not intended for screening, leaving many healthy adults with potential insurance and psychological concerns.
Why it matters
The rise of blood-based Alzheimer's testing creates a gap where patients may receive a high-risk result without a corresponding medical treatment for symptom-free individuals. This shift introduces complex challenges for personal privacy and long-term insurance coverage that are not yet fully protected under current law.
A study of 499 adults with cognitive impairment found that 91.7% of positive blood test results matched traditional brain scan or spinal fluid testing. However, the diagnostic accuracy for asymptomatic individuals remains under investigation, and no approved treatment exists for those findings.
The players
Dr. Gayatri Devi
A neurologist and medical researcher based in New York who authored a JAMA analysis on the ethics of Alzheimer's biomarker testing.
The details
Physicians use these blood tests to identify specific biomarkers associated with Alzheimer's-related brain changes. Because the tests are currently cleared by the FDA only for adults 55 and older with cognitive symptoms, using them for general screening creates significant uncertainty. Current law, specifically the Genetic Information Nondiscrimination Act, provides no coverage for life, disability, or long-term care insurance, leaving patients vulnerable if their biomarker results are known.
Timeline
2024: Medical workgroups proposed conflicting definitions for Alzheimer's disease.
May 2025: The FDA cleared the first blood test for Alzheimer's in symptomatic adults 55 and older.
Oct. 19, 2026: Dr. Gayatri Devi published a Viewpoint in JAMA regarding testing ethics.
Health Landscape
The current medical landscape is shaped by conflicting definitions of Alzheimer's disease put forward by various workgroups since 2024. This evolution in diagnostic capability currently outpaces both clinical treatment options and the scope of the Genetic Information Nondiscrimination Act.
If you are considering biomarker testing, it is worth discussing with your doctor how an asymptomatic result could impact your access to long-term care or disability insurance. Since these tests are not approved for screening, prioritize understanding your specific cognitive symptoms rather than seeking out a test on your own.
The takeaway
A positive biomarker result currently indicates a higher risk for Alzheimer's rather than a certain future. Because no treatments are approved for symptom-free individuals, consider the potential insurance and psychological implications of testing before pursuing diagnostics outside of clear clinical symptoms.
Further reading
For more on the current understanding of brain health and diagnostics, visit the Alzheimer’s section.
Live Poll
Would you want to know if you are at risk for a disease before symptoms appear?
